Advanced search
Start date
Betweenand

Use of Zika virus recombinant proteins for development of diagnostic methods and vaccines

Grant number: 16/05570-8
Support type:Scholarships in Brazil - Doctorate
Effective date (Start): August 01, 2016
Effective date (End): September 30, 2021
Field of knowledge:Biological Sciences - Microbiology - Applied Microbiology
Principal researcher:Luis Carlos de Souza Ferreira
Grantee:Lennon Ramos Pereira
Home Institution: Instituto de Ciências Biomédicas (ICB). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated scholarship(s):19/18205-4 - Identification and characterization of peptides capable to interfere with the infection mechanisms of dengue and zika viruses., BE.EP.DR

Abstract

Zika virus (ZIKV) belongs to Flaviviridae family and the genus flavivirus, like other emerging viruses such as dengue virus (DENV) and yellow fever virus (YFV), transmitted to humans by Aedes mosquitoes. The ZIKV infection is acute and self-limiting, however, severe manifestations such as Guillain-barrée syndrome and the possibility of development of microcephaly in infants emphasize the importance of this arbovirus. There are no effective treatments or vaccines available to the population as well as specific serodiagnosis methods for this infection. In this sense, the search for antigens which have low homology with other flavivirus allow the development of specific serologic tests, and are potential vaccine antigens. Therefore, this project aims to obtain recombinant forms of part of envelope protein (E) and non-structural protein 1 (NS1) of ZIKV which have low homology with other flaviviruses. Once obtained, the proteins will be used for development of specific serologic tests and vaccine formulations capable of eliciting protective immunity against the virus. To this end, domain III of the E protein, and a fragment of NS1 protein (Delta-NS1) of ZIKV will be expressed in a prokaryotic system and purified by affinity chromatography technique. The recombinant antigens will be used to standardize serodiagnosis assays (ELISA, Western blot and immunofluorescence) discriminatory for ZIKV being used specific hyperimmune sera to other Flavivirus (including YFV and DENV), as well, cross-reactivity controls. The EDIII and NS1 ZIKA antigens also will be assessed for their vaccine potential, which will be use in the composition of formulations to be tested in mice model and evaluate the intensity and functionality of the immune responses, as well as the protective potential in a challenge assay. Thus, the knowledge generated from this work will contribute to the development of different methods of specific serodiagnosis and effective vaccine strategies against ZIKV. (AU)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
PEREIRA, LENNON RAMOS; VICENTIN, ELAINE CRISTINA MATOS; PEREIRA, SARA ARAUJO; MAEDA, DENICAR LINA NASCIMENTO FABRIS; ALVES, RUBENS PRINCE DOS SANTOS; ANDREATA-SANTOS, ROBERT; SOUSA, FRANCIELLE TRAMONTINI GOMES DE; YAMAMOTO, MARCIO MASSAO; CASTRO-AMARANTE, MARIA FERNANDA; FAVARO, MARIANNA TEIXEIRA DE PINHO; ROMANO, CAMILA MALTA; SABINO, ESTER CERDEIRA; BOSCARDIN, SILVIA BEATRIZ; FERREIRA, LUIS CARLOS DE SOUZA. Intradermal Delivery of Dendritic Cell-Targeting Chimeric mAbs Genetically Fused to Type 2 Dengue Virus Nonstructural Protein 1. VACCINES, v. 8, n. 4 DEC 2020. Web of Science Citations: 0.
ANDREATA-SANTOS, ROBERT; DOS SANTOS ALVES, RUBENS PRINCE; PEREIRA, SARA ARAUJO; PEREIRA, LENNON RAMOS; DE FREITAS, CARLA LONGO; PEREIRA, SAMUEL SANTOS; VENCESLAU-CARVALHO, ALEXIA ADRIANNE; CASTRO-AMARANTE, MARIA FERNANDA; PINHO FAVARO, MARIANNA TEIXEIRA; MATHIAS-SANTOS, CAMILA; AMORIM, JAIME HENRIQUE; DE SOUZA FERREIRA, LUIS CARLOS. Transcutaneous Administration of Dengue Vaccines. Viruses-Basel, v. 12, n. 5 MAY 2020. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.